Garching/Munich, Germany and Princeton, New Jersey – July 27, 2026
ITM Isotope Technologies Munich SE (ITM) has launched Lumara Bio, a dedicated oncology therapeutics division created to unify the company’s early- and late-stage radiopharmaceutical pipeline under a single organization. The new division will oversee the development and commercialization of ITM’s targeted radiopharmaceutical therapies, including its lead investigational candidate 177Lu-edotreotide (ITM-11), which is currently under U.S. Food and Drug Administration (FDA) review with a Prescription Drug User Fee Act (PDUFA) target date of August 28, 2026. The formation of Lumara Bio reflects ITM’s strategy to strengthen its precision oncology business while accelerating the development of innovative radiopharmaceutical therapies for patients with difficult-to-treat cancers.
Lumara Bio Strengthens Commercial and Clinical Development Strategy
The newly established Lumara Bio division brings together ITM’s existing radiopharmaceutical therapeutic pipeline, development teams, and commercialization resources into a dedicated organization focused on advancing targeted cancer therapies. According to Dr. Andrew Cavey, Chief Executive Officer of ITM, the new structure allows the company to concentrate internal resources on preparations for the potential commercial launch of 177Lu-edotreotide (ITM-11) while continuing to expand its broader oncology portfolio. Beyond supporting commercialization, Lumara Bio will coordinate research, clinical development, regulatory activities, and strategic collaborations to accelerate the advancement of next-generation radiopharmaceutical therapies. The division also highlights ITM’s evolution from an isotope manufacturer into a fully integrated radiopharmaceutical biotechnology company with capabilities spanning discovery, development, manufacturing, and commercialization.
ITM-11 Remains Under FDA Review Ahead of August PDUFA Date
The lead asset within Lumara Bio’s portfolio is 177Lu-edotreotide (ITM-11), a targeted radiopharmaceutical therapy currently undergoing FDA review. The investigational therapy has a PDUFA goal date of August 28, 2026, and ITM confirmed that commercial readiness activities are already underway in anticipation of a potential regulatory approval. While 177Lu-edotreotide has not yet been approved for any indication by regulatory authorities, it represents one of the company’s most advanced oncology programs. In addition to ITM-11, Lumara Bio will continue advancing multiple early- and late-stage radiopharmaceutical candidates targeting a variety of cancer types through different therapeutic approaches and proprietary isotope technologies.
Advertisement
Dedicated Division Expands Precision Oncology Vision
Building on more than two decades of radiopharmaceutical expertise, Lumara Bio will leverage ITM’s established medical radioisotope manufacturing and global supply network to support clinical development and future commercial activities. The division is expected to play a central role in expanding ITM’s precision oncology portfolio by integrating targeted radiopharmaceutical development with reliable isotope production and strategic scientific partnerships. Through its diversified pipeline and specialized infrastructure, Lumara Bio aims to accelerate the delivery of innovative targeted cancer therapies for patients with limited treatment options while reinforcing ITM’s leadership position in the rapidly growing radiopharmaceutical oncology market.
Source: ITM Isotope Technologies Munich press release
